Humulin M3

Humulin M3 is a prescription injectable medication that contains insulin human as its active ingredient. It is supplied in a sterile solution for subcutaneous injection, with the specific strength not disclosed in the provided data. The product is marketed in the European Union and belongs to the insulin class of antidiabetic agents. It is used to replace or supplement endogenous insulin in patients with diabetes mellitus.

Humulin M3 is indicated for the management of hyperglycemia in patients with diabetes mellitus.

- Treatment of type 1 diabetes mellitus requiring insulin replacement. - Treatment of type 2 diabetes mellitus when oral agents are insufficient. - Adjunct to diet and exercise to achieve glycemic targets. - Use in combination with other antidiabetic agents as directed by a healthcare professional. - May be employed during periods of increased insulin demand, such as illness or surgery.

Adverse reactions to Humulin M3 can be grouped by frequency.

Common: - Hypoglycemia (low blood glucose) - Injection‑site pain, redness, or swelling - Lipodystrophy (localized fat tissue changes) - Weight gain - Mild peripheral edema

Serious: - Severe hypoglycemia with neurological impairment - Anaphylactic or severe allergic reactions - Electrolyte disturbances such as hypokalemia or hypocalcemia - Acute insulin overdose leading to coma - Persistent or worsening cardiovascular events related to hypoglycemia

When prescribing Humulin M3, clinicians should consider several safety factors.

- Assess the risk of hypoglycemia, especially in patients with irregular meals or high physical activity. - Adjust doses in renal or hepatic impairment due to altered insulin clearance. - Perform frequent blood glucose monitoring during initiation or dose changes. - Use caution in patients with established cardiovascular disease. - Avoid use in individuals with known hypersensitivity to human insulin or any excipients. - Pregnancy and lactation require a careful risk‑benefit assessment by a qualified provider.

Humulin M3 may interact with other medicines that affect glucose levels or insulin action.

Avoid: - Concurrent use of other rapid‑acting insulins without appropriate dose adjustment. - Beta‑blockers that can mask hypoglycemia symptoms. - Monoamine oxidase (MAO) inhibitors, which may potentiate insulin’s glucose‑lowering effect. - Excessive alcohol consumption, which can precipitate hypoglycemia.

Use with caution: - Thiazide diuretics, which may raise blood glucose. - Systemic corticosteroids, which often require higher insulin doses. - Oral antidiabetic agents (e.g., sulfonylureas) that increase hypoglycemia risk. - ACE inhibitors, which can enhance insulin sensitivity and affect glucose control.